In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness
Identifieur interne : 003169 ( Main/Exploration ); précédent : 003168; suivant : 003170In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness
Auteurs : R. B. Gilbertsen [États-Unis] ; K. M. Cullinen [États-Unis] ; D. J. Wilburn [États-Unis] ; M. K. Dong [États-Unis] ; M. C. Conroy [États-Unis]Source :
- Agents and Actions [ 0065-4299 ] ; 1989-06-01.
English descriptors
- Teeft :
Abstract
Abstract: CI-949 (5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide,l-arginine salt), an antiallergy compound was found to be a weak inhibitor of IL-1 release from LPS-stimulated murine peritoneal exudate cells and human peripheral blood leukocytes, with IC50s of 186.2 and 267.9 μM, respectively. CI-949 was also a poor inhibitor of release of IL-2 from Con A-stimulated rat spelenocytes (37% inhibition at 100 μM). CI-949 did produce concentration-related inhibition of the response of human lymphocytes to PHA and Con A (IC50s=44.7 and 21.5 μM, respectively) as well as in the mixed lymphocyte reaction (MLR) (IC50=16.8 μM). The clinical significance of these latter findings is unknown at present.
Url:
DOI: 10.1007/BF01972805
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B71
- to stream Istex, to step Curation: 000B71
- to stream Istex, to step Checkpoint: 001F34
- to stream Main, to step Merge: 003238
- to stream Main, to step Curation: 003169
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness</title><author><name sortKey="Gilbertsen, R B" sort="Gilbertsen, R B" uniqKey="Gilbertsen R" first="R. B." last="Gilbertsen">R. B. Gilbertsen</name></author><author><name sortKey="Cullinen, K M" sort="Cullinen, K M" uniqKey="Cullinen K" first="K. M." last="Cullinen">K. M. Cullinen</name></author><author><name sortKey="Wilburn, D J" sort="Wilburn, D J" uniqKey="Wilburn D" first="D. J." last="Wilburn">D. J. Wilburn</name></author><author><name sortKey="Dong, M K" sort="Dong, M K" uniqKey="Dong M" first="M. K." last="Dong">M. K. Dong</name></author><author><name sortKey="Conroy, M C" sort="Conroy, M C" uniqKey="Conroy M" first="M. C." last="Conroy">M. C. Conroy</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C378DFC8D338BF7C085A4C0964947BCB1BAF18E4</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1007/BF01972805</idno><idno type="url">https://api.istex.fr/ark:/67375/1BB-211J4R0T-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B71</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B71</idno><idno type="wicri:Area/Istex/Curation">000B71</idno><idno type="wicri:Area/Istex/Checkpoint">001F34</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F34</idno><idno type="wicri:doubleKey">0065-4299:1989:Gilbertsen R:in:vitro:effects</idno><idno type="wicri:Area/Main/Merge">003238</idno><idno type="wicri:Area/Main/Curation">003169</idno><idno type="wicri:Area/Main/Exploration">003169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness</title><author><name sortKey="Gilbertsen, R B" sort="Gilbertsen, R B" uniqKey="Gilbertsen R" first="R. B." last="Gilbertsen">R. B. Gilbertsen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Cullinen, K M" sort="Cullinen, K M" uniqKey="Cullinen K" first="K. M." last="Cullinen">K. M. Cullinen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Wilburn, D J" sort="Wilburn, D J" uniqKey="Wilburn D" first="D. J." last="Wilburn">D. J. Wilburn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Dong, M K" sort="Dong, M K" uniqKey="Dong M" first="M. K." last="Dong">M. K. Dong</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Conroy, M C" sort="Conroy, M C" uniqKey="Conroy M" first="M. C." last="Conroy">M. C. Conroy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Agents and Actions</title><title level="j" type="abbrev">Agents and Actions</title><idno type="ISSN">0065-4299</idno><idno type="eISSN">1420-908X</idno><imprint><publisher>Birkhäuser-Verlag</publisher><pubPlace>Basel</pubPlace><date type="published" when="1989-06-01">1989-06-01</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">3-4</biblScope><biblScope unit="page" from="303">303</biblScope><biblScope unit="page" to="305">305</biblScope></imprint><idno type="ISSN">0065-4299</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0065-4299</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Allergy clin</term><term>Antiallergy compound</term><term>Blood leukocytes</term><term>Clinical significance</term><term>Conroy</term><term>Data points</term><term>Histamine</term><term>Hpbl</term><term>Human lymphocyte cultures</term><term>Human lymphocytes</term><term>Immunol</term><term>Leukocyte</term><term>Lymphocyte</term><term>Mitogen</term><term>Mpec</term><term>Murine</term><term>Murine cell line</term><term>Pharmacological profile</term><term>Weak inhibitor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: CI-949 (5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide,l-arginine salt), an antiallergy compound was found to be a weak inhibitor of IL-1 release from LPS-stimulated murine peritoneal exudate cells and human peripheral blood leukocytes, with IC50s of 186.2 and 267.9 μM, respectively. CI-949 was also a poor inhibitor of release of IL-2 from Con A-stimulated rat spelenocytes (37% inhibition at 100 μM). CI-949 did produce concentration-related inhibition of the response of human lymphocytes to PHA and Con A (IC50s=44.7 and 21.5 μM, respectively) as well as in the mixed lymphocyte reaction (MLR) (IC50=16.8 μM). The clinical significance of these latter findings is unknown at present.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Gilbertsen, R B" sort="Gilbertsen, R B" uniqKey="Gilbertsen R" first="R. B." last="Gilbertsen">R. B. Gilbertsen</name></region><name sortKey="Conroy, M C" sort="Conroy, M C" uniqKey="Conroy M" first="M. C." last="Conroy">M. C. Conroy</name><name sortKey="Cullinen, K M" sort="Cullinen, K M" uniqKey="Cullinen K" first="K. M." last="Cullinen">K. M. Cullinen</name><name sortKey="Dong, M K" sort="Dong, M K" uniqKey="Dong M" first="M. K." last="Dong">M. K. Dong</name><name sortKey="Wilburn, D J" sort="Wilburn, D J" uniqKey="Wilburn D" first="D. J." last="Wilburn">D. J. Wilburn</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C378DFC8D338BF7C085A4C0964947BCB1BAF18E4
|texte= In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness
}}
| This area was generated with Dilib version V0.6.33. |  |